Clinical Trial Update: Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and safety of voretigene neparvovec in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rpe65-related Retinal Dystrophy

Drugs mentioned

• Voretigene Neparvovec (voretigene neparvovec)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Biallelic RPE65 Mutation-associated Retinal Dystrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING